• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CHLORPROMAZINE Drug Record

  • Summary
  • Interactions
  • Claims
  • CHLORPROMAZINE chembl:CHEMBL71 Approved

    Alternate Names:

    CHLORPROMAZINE TANNATE
    LARGACTIL
    MEGAPHEN
    CHLORPROMAZINE HIBENZATE
    SONAZINE
    SKF-2601A
    J2.794D
    CHLORPROMAZINE PHENOLPHTHALINATE
    NSC-167745
    ELMARIN
    CHLORPROMAZINE
    THORAZINE
    NSC-226514
    3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)-N,N-DIMETHYL-1-PROPANAMINE
    N-(3-DIMETHYLAMINOPROPYL)-3-CHLOROPHENOTHIAZINE
    CPZ
    LARGACTIL®
    3-(2-CHLOROPHENOTHIAZIN-10-YL)-N,N-DIMETHYL-PROPAN-1-AMINE
    CHLORPROMAZINE HCL
    THORAZINE®
    rxcui:2403
    chemidplus:50-53-3
    drugbank:00477
    chembl:CHEMBL71
    pubchem.compound:2726

    Drug Info:

    Drug Categories phenothiazines with aliphatic side-chain
    Drug Groups investigational
    Drug Categories adrenergic alpha-1 receptor antagonists
    Drug Categories adrenergic alpha-antagonists
    Drug Categories adrenergic antagonists
    Drug Categories agents producing tachycardia
    Drug Categories agents that produce hypertension
    Drug Categories agents that reduce seizure threshold
    Drug Categories anticholinergic agents
    Drug Categories antidepressive agents
    Drug Categories cholinesterase inhibitors
    Drug Categories cytochrome p-450 cyp2d6 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2e1 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a inducers
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 inducers
    Drug Categories cytochrome p-450 cyp3a4 inducers (strength unknown)
    Drug Categories cytochrome p-450 cyp3a4 substrates (strength unknown)
    Drug Categories cytochrome p-450 enzyme inducers
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories dopamine d2 receptor antagonists
    Drug Categories drugs causing inadvertant photosensitivity
    Drug Categories drugs that are mainly renally excreted
    Drug Categories heterocyclic compounds, fused-ring
    Drug Categories histamine antagonists
    Drug Categories histamine h1 antagonists
    Drug Categories hyperglycemia-associated agents
    Drug Categories muscarinic antagonists
    Drug Categories neurotoxic agents
    Drug Categories p-glycoprotein inhibitors
    Drug Categories p-glycoprotein substrates
    Drug Categories photosensitizing agents
    Drug Categories qtc prolonging agents
    Drug Categories serotonergic drugs shown to increase risk of serotonin syndrome
    Drug Categories serotonin 5-ht1 receptor antagonists
    Drug Categories serotonin 5-ht2 receptor antagonists
    Drug Categories serotonin agents
    Drug Categories serotonin receptor antagonists
    (4 More Sources)

    Publications:

    Roth et al., 1994, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors., J. Pharmacol. Exp. Ther.
    Yamada et al., 1995, Serotonin2 (5-HT2) receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) inhibits chlorpromazine- and haloperidol-induced hypothermia in mice., Biol. Pharm. Bull.
    Kusumi et al., 2000, Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain., J Neural Transm (Vienna)
    Seeman et al., 1993, Dopamine receptor pharmacology., Curr Opin Neurol Neurosurg
    Kanba et al., 1994, Affinity of neuroleptics for D1 receptor of human brain striatum., J Psychiatry Neurosci
    Nguyen et al., 2001, Discovery of a novel member of the histamine receptor family., Mol. Pharmacol.
    Xu et al., 2008, BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population., Pharmacogenet. Genomics
    Roth et al., 1995, D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs., Psychopharmacology (Berl.)
    Davies et al., 2005, The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?, Psychopharmacology (Berl.)
    Huerta-Bahena et al., 1983, Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects., Mol. Pharmacol.
    Cahir et al., 2005, Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat., Eur Neuropsychopharmacol
    Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
    Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
    Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
    Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
    Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
    Wu et al., 2006, Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients., Acta Pharmacol. Sin.
    Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
    Oades et al., 2000, Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy., Behav Pharmacol
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
    Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
    Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
    Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
    Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
    Seeman, 2010, Dopamine D2 receptors as treatment targets in schizophrenia., Clin Schizophr Relat Psychoses
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Tay JK et al., 2007, Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry
    Ruffolo et al., 1978, Kinetics of blockade of different receptors by chlorpromazine in rabbit stomach strips., Eur. J. Pharmacol.
    Johnson et al., 1979, Inhibition of histamine release and ionophore-induced calcium flux in rat mast cells by lidocaine and chlorpromazine., Agents Actions
    Palmer et al., 1978, Histamine-, norepinephrine-, and dopamine-sensitive central adenylate cyclases: effects of chlorpromazine derivatives and butaclamol., Arch Int Pharmacodyn Ther
    Church et al., 1983, The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine., Br. J. Pharmacol.
    Hals et al., 1988, Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites., Life Sci.
    Bylund et al., 1988, Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype., J. Pharmacol. Exp. Ther.
    Marshak et al., 1985, Drug-protein interactions: binding of chlorpromazine to calmodulin, calmodulin fragments, and related calcium binding proteins., Biochemistry
    Muralidharan G et al., 1996, Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine., Eur J Clin Pharmacol
    Cosi et al., 2001, Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells., Eur. J. Pharmacol.
    Newman-Tancredi et al., 1998, Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study., Eur. J. Pharmacol.
    Freedman et al., 1994, Expression and pharmacological characterization of the human D3 dopamine receptor., J. Pharmacol. Exp. Ther.
    Monostory et al., 2004, Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors., Chem. Biol. Interact.
    Thomas et al., 2003, The antipsychotic drug chlorpromazine inhibits HERG potassium channels., Br. J. Pharmacol.
    Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
    Pomeranz et al., 1987, The effect of chlorpromazine on cholecystokinin induced gallbladder contraction., Proc. West. Pharmacol. Soc.
    Giardino et al., 1990, DA2/NT receptor balance in the mesostriatal and mesolimbocortical systems after chronic treatment with typical and atypical neuroleptic drugs., Brain Res.
    Wang et al., 2008, Antipsychotic drugs inhibit the function of breast cancer resistance protein., Basic Clin. Pharmacol. Toxicol.
    Yoshida et al., 1985, Reduction of acid sphingomyelinase activity in human fibroblasts induced by AY-9944 and other cationic amphiphilic drugs., J. Biochem.
    Wang et al., 2006, Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein., Psychopharmacology (Berl.)
    Hervé et al., 1996, Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein., Pharmacogenetics
    Liu et al., 2003, Calmodulin is involved in heat shock signal transduction in wheat., Plant Physiol.
  • CHLORPROMAZINE   CCK

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3628280


    Sources:
    NCI

  • CHLORPROMAZINE   SMPD1

    Interaction Score: 0.57

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    2419314


    Sources:
    DrugBank

  • CHLORPROMAZINE   ORM1

    Interaction Score: 0.47

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    8946472


    Sources:
    DrugBank

  • CHLORPROMAZINE   EPM2A

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27092952


    Sources:
    PharmGKB

  • CHLORPROMAZINE   NTS

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1980851


    Sources:
    NCI

  • CHLORPROMAZINE   DRD2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist
    Mechanism of Interaction D2-like dopamine receptor antagonist

    PMIDs:
    7908055 15694263 28673279 11505224 17105675 18926547 16867246 11873706 11103886 11752352 9858029 15830237 16513877 8524985 20194480 9918131 20643630


    Sources:
    PharmGKB TTD DrugBank GuideToPharmacology ChemblInteractions

  • CHLORPROMAZINE   CYP2E1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15135088


    Sources:
    NCI

  • CHLORPROMAZINE   DRD5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    8104554


    Sources:
    DrugBank GuideToPharmacology

  • CHLORPROMAZINE   CALM1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    2986673


    Sources:
    DrugBank

  • CHLORPROMAZINE   TRPC5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand None

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • CHLORPROMAZINE   HSPA4

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12857801


    Sources:
    NCI

  • CHLORPROMAZINE   HTR7

    Interaction Score: 0.09

    Interaction Types & Directionality:
    binder
    antagonist (inhibitory)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Inverse agonist

    PMIDs:
    7908055


    Sources:
    NCI DrugBank GuideToPharmacology

  • CHLORPROMAZINE   HTR6

    Interaction Score: 0.08

    Interaction Types & Directionality:
    binder
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inverse agonist
    Endogenous Drug? False

    PMIDs:
    7908055


    Sources:
    DrugBank GuideToPharmacology

  • CHLORPROMAZINE   HRH4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    binder

    Interaction Info:

    PMIDs:
    11179435


    Sources:
    DrugBank

  • CHLORPROMAZINE   DRD4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    binder
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Specific Action of the Ligand Antagonist

    PMIDs:
    8524985


    Sources:
    DrugBank GuideToPharmacology ChemblInteractions

  • CHLORPROMAZINE   DRD3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False
    Mechanism of Interaction D2-like dopamine receptor antagonist

    PMIDs:
    8301582


    Sources:
    DrugBank GuideToPharmacology ChemblInteractions

  • CHLORPROMAZINE   HRH1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    25190 91313 687395 6189542 2899826


    Sources:
    DrugBank GuideToPharmacology

  • CHLORPROMAZINE   HTR2A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    binder
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2a (5-HT2a) receptor antagonist
    Direct Interaction yes
    Specific Action of the Ligand Inverse agonist

    PMIDs:
    7908055 8593484 10821438


    Sources:
    DrugBank GuideToPharmacology ChemblInteractions

  • CHLORPROMAZINE   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18834354


    Sources:
    NCI

  • CHLORPROMAZINE   BDNF

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18408624


    Sources:
    NCI

  • CHLORPROMAZINE   HTR1A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    11755134 9760039


    Sources:
    DrugBank GuideToPharmacology

  • CHLORPROMAZINE   HTR2C

    Interaction Score: 0.03

    Interaction Types & Directionality:
    binder
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    7908055


    Sources:
    DrugBank GuideToPharmacology

  • CHLORPROMAZINE   ADRA2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    2835476


    Sources:
    DrugBank GuideToPharmacology

  • CHLORPROMAZINE   DRD1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    8104554 7918347


    Sources:
    DrugBank GuideToPharmacology

  • CHLORPROMAZINE   ADRA1B

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    15695070


    Sources:
    DrugBank

  • CHLORPROMAZINE   ADRA1A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    6135146 15695070


    Sources:
    DrugBank

  • CHLORPROMAZINE   CHRM3

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    15765260


    Sources:
    DrugBank

  • CHLORPROMAZINE   THPO

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHLORPROMAZINE   CHRM1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    15765260


    Sources:
    DrugBank

  • CHLORPROMAZINE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16810505


    Sources:
    NCI PharmGKB

  • CHLORPROMAZINE   ADRA2B

    Interaction Score: 0.02

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • CHLORPROMAZINE   ADRA2C

    Interaction Score: 0.01

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • CHLORPROMAZINE   NR1I2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CHLORPROMAZINE   KCNH2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    12788816


    Sources:
    DrugBank

  • CHLORPROMAZINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17611010


    Sources:
    DTC PharmGKB

  • CHLORPROMAZINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8739822


    Sources:
    DTC PharmGKB

  • CHLORPROMAZINE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CHLORPROMAZINE   TP53

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHLORPROMAZINE   IDH1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHLORPROMAZINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DrugBank: DB00477

    • Version: 5.1.7

    Alternate Names:
    CHLORPROMAZINE DrugBank Drug Name
    50-53-3 CAS Number
    Aminazine Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Seeman et al., 1993, Dopamine receptor pharmacology., Curr Opin Neurol Neurosurg
    Cahir et al., 2005, Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat., Eur Neuropsychopharmacol
    Thomas et al., 2003, The antipsychotic drug chlorpromazine inhibits HERG potassium channels., Br. J. Pharmacol.

  • NCI: CHLORPROMAZINE

    • Version: 14-September-2017

    Alternate Names:
    C367 NCI drug code

    Drug Info:

    Publications:
    Xu et al., 2008, BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population., Pharmacogenet. Genomics
    Monostory et al., 2004, Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors., Chem. Biol. Interact.
    Wang et al., 2008, Antipsychotic drugs inhibit the function of breast cancer resistance protein., Basic Clin. Pharmacol. Toxicol.

  • DTC: CHLORPROMAZINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL71 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: chlorpromazine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
    Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
    Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics

  • TTD: Chlorpromazine

    • Version: 2020.06.01

    Alternate Names:
    D01ZII TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 135650088

    • Version: 29-September-2020

    Alternate Names:
    CHLORPROMAZINE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL71

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL71

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21